PRETREATMENT WITH ALBUTEROL VS MONTELUKAST IN EXERCISE INDUCED BRONCHOSPASM IN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们的假设是，与孟鲁司特相比，沙丁胺醇预处理对轻度哮喘儿童的突破性EIB具有更好的保护作用，因为它是目前阿斯玛方案的维持疗法的补充。这项研究的次要目的是测量孟鲁司特对EBC中白三烯B4(LTB4)浓度的影响，以及通过FeNO水平测量对炎症的影响。我们假设，由于孟鲁司特是一种半胱氨酸基，在EBC中测量，而在炎症上测量FeNO水平。我们推测，由于莫鲁司特是一种半胱氨酰白三烯受体拮抗剂，因此LTB4浓度升高的患者对该药物的反应可能更大。最后，FeNO升高的患者对阿鲁特罗和孟鲁司特的反应不同。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. It is our hypothesis that pretreatment with albuterol will provide superior protection against breakthrough EIB in children with mild asthma compared to montelukast as maintenance therapy added to the current athma regimen. Secondary aims of this study are to measure the effect of montelukast on leukotriene B4 (LTB4) concentrations as measured in EBC, and on inflammation measured by FeNO level. We hypothesize that since montelukast is a cysteinyl measured in EBC, and on inflammation measured by FeNO level. We hypothesize that since motelukast is a cysteinyl leukotriene receptor antagonist, patients with elevated concentration of LTB4 may have a greater response to this mediction. Lastly, patients with elevated FeNo, a measure of airway inflammation respond differently to alubterol than montelukast.